Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Marker Therapeutics, Inc.MRKR · Entity 7609 | Vice President, Clinical Ops. | February 17, 2022 | February 22, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Marker Therapeutics, Inc.
Report date February 17, 2022 · Filed February 22, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.46 · Expires 2032-02-17 | Direct | 40,000 |
Reported balance
After 2022-02-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-02-17 · Grant · Acquired 40,000 · Balance 40,000 F1: This option vests in equal monthly installments over a four year period commencing on March 17, 2022 subject to the continued service by the Reporting Person to the Issuer as of the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option vests in equal monthly installments over a four year period commencing on March 17, 2022 subject to the continued service by the Reporting Person to the Issuer as of the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 17, 2022 Filed Feb 22, 2022 17:02 UTC | Marker Therapeutics, Inc. MRKR · Entity 7609 | GrantEmployee Stock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $0.46 | $0.00 |
DisclosureSEC source: 0001209191-22-011761 · doc4.xml · derivative · entry 1 Garrett Gerald · CIK 0001804510 · Vice President, Clinical Ops. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2032-02-17 F1 · derivative.exercise_date: This option vests in equal monthly installments over a four year period commencing on March 17, 2022 subject to the continued service by the Reporting Person to the Issuer as of the applicable vesting date. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 17:23 UTC | Marker Therapeutics, Inc. MRKR · Entity 7609 | GrantEmployee Stock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $3.29 | $0.00 |
DisclosureSEC source: 0001209191-21-010262 · doc4.xml · derivative · entry 1 Garrett Gerald · CIK 0001804510 · Vice President, Clinical Ops. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2031-02-10 F1 · derivative.exercise_date: This option vests in equal monthly installments over a four year period commencing on March 10, 2021 subject to the continued service by the Reporting Person to the Issuer as of the applicable vesting date. Read SEC document |
| March 10, 2020 Filed Mar 12, 2020 16:36 UTC | Marker Therapeutics, Inc. MRKR · Entity 7609 | GrantEmployee Stock Option (Right to Buy) · Derivative | 38,300 | $0.00 Strike: $2.12 | $0.00 |
DisclosureSEC source: 0001209191-20-018528 · doc4.xml · derivative · entry 2 Garrett Gerald · CIK 0001804510 · Vice President, Clinical Ops. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,300 Underlying: Common Stock · 38,300 shares Expires 2030-03-10 F2 · derivative.exercise_date: This option vests in equal monthly installments over a four year period commencing on April 10, 2020 subject to the continued service by the Reporting Person to the Issuer as of the applicable vesting date. Read SEC document |
| March 10, 2020 Filed Mar 12, 2020 16:36 UTC | Marker Therapeutics, Inc. MRKR · Entity 7609 | GrantEmployee Stock Option (Right to Buy) · Derivative | 1,700 | $0.00 Strike: $2.12 | $0.00 |
DisclosureSEC source: 0001209191-20-018528 · doc4.xml · derivative · entry 1 Garrett Gerald · CIK 0001804510 · Vice President, Clinical Ops. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,700 Underlying: Common Stock · 1,700 shares Expires 2030-03-10 F1 · derivative.exercise_date: Represents a bonus for 2019 performance granted under the Company's 2014 Omnibus Stock Ownership Plan. This option vests in equal monthly installments over a four year period commencing on April 10, 2020 subject to the continued service by the Reporting Person to the Issuer as of the applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.